CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) rose 7.8% during mid-day trading on Friday . The stock traded as high as $0.15 and last traded at $0.14. 1,923,801 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 2,548,531 shares. The stock had previously closed at $0.13.
CytoDyn Price Performance
The firm’s 50-day moving average price is $0.13 and its 200 day moving average price is $0.14. The firm has a market capitalization of $168.27 million, a price-to-earnings ratio of -6.90 and a beta of 0.14.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- How to Capture the Benefits of Dividend Increases
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- How to Read Stock Charts for Beginners
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
